|
吉田 一彦
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Assistant Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. |
| Journal | Formal name：Anticancer research Abbreviation：Anticancer Res ISSN code：02507005/17917530 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 41(3),pp.1607-1614 |
| Author and coauthor | ISHIYAMA Yudai†, KONDO Tsunenori*, NEMOTO Yuki, KOBARI Yuki, ISHIHARA Hiroki, TACHIBANA Hidekazu, YOSHIDA Kazuhiko, HASHIMOTO Yasunobu, TAKAGI Toshio, IIZUKA Junpei, TANABE Kazunari |
| Publication date | 2021/03 |
| Summary | BACKGROUND/AIM:We investigated the prognostic nutritional index (PNI), comprised of lymphocytes and albumin, as a potential prognosticator of metastatic urothelial carcinoma (mUC) patients receiving pembrolizumab.PATIENTS AND METHODS:Sixty-five patients were retrospectively enrolled and classified as low (<40) and high (≥40) based on pretreatment PNI. Progression-free survival (PFS), overall survival (OS) and response rates were evaluated.RESULTS:In the low PNI group, significantly shorter PFS and OS were observed. PNI was shown to be an independent predictor of PFS and OS in the multivariate analysis. C-index for both PFS and OS improved with the addition of PNI to the model described in the KEYNOTE-045 study. Significantly more patients experienced initial disease progression in the low PNI group.CONCLUSION:PNI is a useful predictor of prognosis and disease progression in mUC patients receiving pembrolizumab. |
| DOI | 10.21873/anticanres.14922 |
| PMID | 33788756 |